Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s617. https://doi.org/10.25251/gf6mb511